Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation
Although CD19-directed chimeric antigen receptor (CAR) T cells have been successfully used after a preceding allogeneic stem cell transplant (alloHCT) in patients with acute lymphoblastic leukemia, little is known about the feasibility and outcome of CAR T cell treatment in patients who have been pr...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 May 2020
|
| In: |
Biology of blood and marrow transplantation
Year: 2020, Jahrgang: 26, Heft: 9, Pages: 1575-1580 |
| ISSN: | 1523-6536 |
| DOI: | 10.1016/j.bbmt.2020.04.025 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.bbmt.2020.04.025 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S1083879120302585 
|
| Verfasserangaben: | Maria-Luisa Schubert, Sascha Dietrich, Stephan Stilgenbauer, Anita Schmitt, Petra Pavel, Alexander Kunz, Andrea Bondong, Mandy Wegner, Peter Stadtherr, Susanne Jung, Anthony D. Ho, Carsten Müller-Tidow, Michael Schmitt, Peter Dreger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1741227879 | ||
| 003 | DE-627 | ||
| 005 | 20230428021747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201126s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbmt.2020.04.025 |2 doi | |
| 035 | |a (DE-627)1741227879 | ||
| 035 | |a (DE-599)KXP1741227879 | ||
| 035 | |a (OCoLC)1341382766 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schubert, Maria-Luisa |d 1982- |e VerfasserIn |0 (DE-588)1147867631 |0 (DE-627)1007273801 |0 (DE-576)49608089X |4 aut | |
| 245 | 1 | 0 | |a Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation |c Maria-Luisa Schubert, Sascha Dietrich, Stephan Stilgenbauer, Anita Schmitt, Petra Pavel, Alexander Kunz, Andrea Bondong, Mandy Wegner, Peter Stadtherr, Susanne Jung, Anthony D. Ho, Carsten Müller-Tidow, Michael Schmitt, Peter Dreger |
| 264 | 1 | |c 15 May 2020 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.11.2020 | ||
| 520 | |a Although CD19-directed chimeric antigen receptor (CAR) T cells have been successfully used after a preceding allogeneic stem cell transplant (alloHCT) in patients with acute lymphoblastic leukemia, little is known about the feasibility and outcome of CAR T cell treatment in patients who have been previously allotransplanted for lymphoma. In a single-center retrospective analysis, course and outcome of all allografted patients treated with CD19 CAR constructs for B cell lymphoma between October 2018 and November 2019 were studied. CAR therapy consisted either of a third-generation CAR (HD-CAR-1) or of commercially manufactured axicabtagene ciloleucel (axi-cel; Gilead, Santa Monica, U.S.). Altogether, 10 CAR T cell dosings using recipient leukapheresis products were performed in 8 patients: 4 patients (2 mantle cell lymphoma, 2 chronic lymphocytic leukemia) received 6 dosings with HD-CAR-1 and 4 patients (all with diffuse large B cell lymphoma) received 4 dosings with axi-cel. Overall, 6 of 8 patients (75%) responded. CAR treatment was well tolerated with grade ≥ 3 cytokine release syndrome and neurotoxicity each being observed after 1 of 10 dosings. A single patient had moderate chronic graft-versus-host disease. Of note, 3 of 4 patients who received axi-cel had ongoing grade ≥ 3 cytopenia 3 months postdosing, whereas prolonged cytopenia was not observed in 9 alloHCT-naive patients who received axi-cel during the same time period. In conclusion, CAR T cell treatment from recipient-derived leukapheresis products after a prior alloHCT appears to be feasible, effective, and safe in patients with B cell lymphoma. Protracted cytopenia after axi-cel treatment is a matter of concern and requires further exploration. | ||
| 650 | 4 | |a Allogeneic-stem cell transplantation | |
| 650 | 4 | |a B-cell lymphoma | |
| 650 | 4 | |a Chimeric antigen receptor (CAR) T cells | |
| 700 | 1 | |a Dietrich, Sascha |d 1979- |e VerfasserIn |0 (DE-588)136406300 |0 (DE-627)694354635 |0 (DE-576)301003408 |4 aut | |
| 700 | 1 | |a Schmitt, Anita |d 1969- |e VerfasserIn |0 (DE-588)141722495 |0 (DE-627)630587752 |0 (DE-576)325593892 |4 aut | |
| 700 | 1 | |a Kunz, Alexander |e VerfasserIn |0 (DE-588)1195494173 |0 (DE-627)1677545046 |4 aut | |
| 700 | 1 | |a Bondong, Andrea |e VerfasserIn |0 (DE-588)106584851X |0 (DE-627)816875502 |0 (DE-576)425539857 |4 aut | |
| 700 | 1 | |a Stadtherr, Peter |e VerfasserIn |0 (DE-588)1065847971 |0 (DE-627)816874557 |0 (DE-576)425538737 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biology of blood and marrow transplantation |d [Erscheinungsort nicht ermittelbar] : Elsevier Health Sciences, 1998 |g 26(2020), 9, Seite 1575-1580 |h Online-Ressource |w (DE-627)334374782 |w (DE-600)2057605-5 |w (DE-576)118352229 |x 1523-6536 |7 nnas |a Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:9 |g pages:1575-1580 |g extent:6 |a Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bbmt.2020.04.025 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1083879120302585 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201126 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 14 |y j | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 1065847971 |a Stadtherr, Peter |m 1065847971:Stadtherr, Peter |d 910000 |d 910100 |e 910000PS1065847971 |e 910100PS1065847971 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 1195494173 |a Kunz, Alexander |m 1195494173:Kunz, Alexander |d 910000 |d 910100 |e 910000PK1195494173 |e 910100PK1195494173 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 141722495 |a Schmitt, Anita |m 141722495:Schmitt, Anita |d 910000 |d 910100 |d 50000 |e 910000PS141722495 |e 910100PS141722495 |e 50000PS141722495 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 4 | ||
| 998 | |g 136406300 |a Dietrich, Sascha |m 136406300:Dietrich, Sascha |d 910000 |d 910100 |d 50000 |e 910000PD136406300 |e 910100PD136406300 |e 50000PD136406300 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 2 | ||
| 998 | |g 1147867631 |a Schubert, Maria-Luisa |m 1147867631:Schubert, Maria-Luisa |d 910000 |d 910100 |e 910000PS1147867631 |e 910100PS1147867631 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1741227879 |e 381348159X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Maria-Luisa","display":"Schubert, Maria-Luisa","family":"Schubert","role":"aut"},{"family":"Dietrich","display":"Dietrich, Sascha","given":"Sascha","role":"aut"},{"family":"Schmitt","display":"Schmitt, Anita","given":"Anita","role":"aut"},{"role":"aut","family":"Kunz","given":"Alexander","display":"Kunz, Alexander"},{"role":"aut","display":"Bondong, Andrea","given":"Andrea","family":"Bondong"},{"role":"aut","family":"Stadtherr","display":"Stadtherr, Peter","given":"Peter"},{"family":"Ho","given":"Anthony Dick","display":"Ho, Anthony Dick","role":"aut"},{"family":"Müller-Tidow","given":"Carsten","display":"Müller-Tidow, Carsten","role":"aut"},{"display":"Schmitt, Michael","given":"Michael","family":"Schmitt","role":"aut"},{"role":"aut","given":"Peter","display":"Dreger, Peter","family":"Dreger"}],"name":{"displayForm":["Maria-Luisa Schubert, Sascha Dietrich, Stephan Stilgenbauer, Anita Schmitt, Petra Pavel, Alexander Kunz, Andrea Bondong, Mandy Wegner, Peter Stadtherr, Susanne Jung, Anthony D. Ho, Carsten Müller-Tidow, Michael Schmitt, Peter Dreger"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"15 May 2020"}],"recId":"1741227879","title":[{"title":"Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation","title_sort":"Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation"}],"language":["eng"],"physDesc":[{"extent":"6 S."}],"id":{"eki":["1741227879"],"doi":["10.1016/j.bbmt.2020.04.025"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 26.11.2020"],"relHost":[{"disp":"Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantationBiology of blood and marrow transplantation","recId":"334374782","titleAlt":[{"title":"BBMT"}],"language":["eng"],"pubHistory":["Volume 4, issue 1 (June 1998)-Volume 26, issue 12 (December 2020)"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Elsevier Health Sciences ; Carden Jennings","dateIssuedDisp":"[1998-2020]","publisherPlace":"[Erscheinungsort nicht ermittelbar] ; Charlottesville, Va."}],"title":[{"title":"Biology of blood and marrow transplantation","title_sort":"Biology of blood and marrow transplantation","subtitle":"BBMT ; the official journal of the American Society for Blood and Marrow Transplantation"}],"id":{"issn":["1523-6536"],"zdb":["2057605-5"],"eki":["334374782"]},"part":{"pages":"1575-1580","year":"2020","volume":"26","text":"26(2020), 9, Seite 1575-1580","issue":"9","extent":"6"},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 16.03.2021"]}]} | ||
| SRT | |a SCHUBERTMAFEASIBILIT1520 | ||